Phylogeny  
• CAMK group → AMPK/SNF1‐related subfamily → MARK branch (marx2006structuralvariationsin pages 1-1)  
• Orthologs: S. cerevisiae KIN1/KIN2, S. pombe kin1, C. elegans PAR-1, D. melanogaster PAR-1, X. laevis XPAR-1A/B, R. norvegicus Mark2, M. musculus Mark2, Homo sapiens MARK1/3/4 (unknownauthors2007regulationofthe pages 7-11)  
• Phylogenomic survey across 94 eukaryotes retains MARK kinases as a conserved LECA-derived clade within CAMK (wijk2020thefirsteukaryotic pages 5-8)  
• Shared domain architecture and sequence homology link MARK2 to other AMPK-family members such as BRSK and SIK (matenia2009thetauof pages 1-2)  

Reaction Catalyzed  
ATP + [protein]-Ser/Thr → ADP + [protein]-O-phospho-Ser/Thr (panneerselvam2006structureofthe pages 1-2)  

Cofactor Requirements  
• Two Mg²⁺ ions coordinate ATP and the catalytic Asp193 for phosphoryl transfer (ahrari2017interconversionofinactive pages 19-21)  

Substrate Specificity  
• Preferred consensus: K-X-G-S*/T* motif identified on MAP2/4 and TAU repeats (panneerselvam2006structureofthe pages 1-2)  
• Basophilic, serine-directed profile; Met at DFG + 1 correlates with weaker sequence stringency yet serine preference (sugiyama2019largescalediscoveryof pages 6-8)  

Structure  
• Domain layout: N-terminal leader | bilobed catalytic domain (Lys82–Asp199 core) | UBA | proline-rich spacer | C-terminal tail with KA1 (panneerselvam2006structureofthe pages 1-2)  
• Experimental structures: human catalytic-UBA 1Y8G (2.6 Å); additional MARK2 entries 1ZMU/1ZMV/1ZMW; rat MARK2 model 2WZJ (panneerselvam2006structureofthe pages 11-11, jenardhanan2014thestructuralanalysis pages 23-25)  
• Active state: pThr208 orders the activation loop, completes Lys82–Glu100 salt bridge and regulatory spine assembly (ahrari2017interconversionofinactive pages 19-21)  
• Inactive state: αC-out, wide catalytic cleft, partially disordered loop; UBA clamps N-lobe restricting inter-lobe motion (panneerselvam2006structureofthe pages 8-9)  
• UBA autoinhibition reduces responsiveness to T208 phosphorylation (unknownauthors2006structuralvariationsin pages 10-13)  
• Unique structural element: β9 strand Asn198-Glu199 forms an atypical RD pocket; DFG remains Asp-in in both states (ahrari2017interconversionofinactive pages 19-21)  

Regulation  
Phosphorylation  
– Thr208: activating, by LKB1 or MARKK/TAO-1 (panneerselvam2006structureofthe pages 1-2)  
– Ser212: inhibitory, by GSK3β (timm2008structureandregulation pages 4-5)  
– Ser409: inhibitory, by PKA (deng2015proteinkinasea pages 8-10)  
– Ser400: inhibitory, by PKD (deng2015proteinkinasea pages 8-10)  
– Thr595: inhibitory, by aPKC; creates 14-3-3 docking site (deng2015proteinkinasea pages 8-10)  
– Ser92 & Thr294: modulatory, by CaMKI (deng2015proteinkinasea pages 8-10)  

Ubiquitination  
• E3 ligases TRAF2 and Smurf1 tag MARK2 for proteasomal degradation (deng2015proteinkinasea pages 8-10)  

Protein/Domain interactions  
• 14-3-3 binds pThr595 or pSer409, sequestering and inhibiting the kinase (deng2015proteinkinasea pages 8-10, timm2008structureandregulation pages 4-5)  
• PAK5 associates with the catalytic domain and suppresses activity (timm2008structureandregulation pages 4-5)  

Function  
• Phosphorylates MAPT/TAU, MAP2 and MAP4 at KXGS sites, detaching them from microtubules and promoting turnover (panneerselvam2006structureofthe pages 1-2)  
• Controls neuronal polarity, axon specification and neurite extension (timm2008structureandregulation pages 4-5)  
• Regulates epithelial polarity via phosphorylation of RAB11FIP2 (panneerselvam2006structureofthe pages 1-2)  
• Upstream activators: LKB1-STRAD-MO25 complex and MARKK/TAO-1 (panneerselvam2006structureofthe pages 1-2)  
• Downstream effects include modulation of WNT/β-catenin signalling; loss-of-function variants suppress pathway activity in neural progenitors (gong2024mark2variantscause pages 3-4)  
• PKA-mediated Ser409 phosphorylation counteracts MARK2-induced microtubule destabilization in neurons (deng2015proteinkinasea pages 8-10)  

Inhibitors  
• 9-oxo-9H-acridin-10-yl derivatives (e.g., 30019, 30195, 30197, 30199) occupy the ATP hinge (Tyr131) and show favourable binding free energy in MARK2 models (jenardhanan2014thestructuralanalysis pages 13-15, jenardhanan2014thestructuralanalysis pages 21-23)  
• Broad-spectrum ATP-competitive compounds OTSSP167 and AZ13599185 reported to inhibit MARK family kinases (annadurai2017microtubuleaffinityregulatingkinases pages 11-11)  

Other Comments  
• Hyperphosphorylation of TAU by MARK2 contributes to Alzheimer-type neurofibrillary pathology (panneerselvam2006structureofthe pages 1-2, timm2008structureandregulation pages 4-5)  
• Pathogenic missense variants p.A80V, p.G135R, p.F194S, p.R302Q (kinase domain) and p.V752A, p.R764P (KA1) destabilize the protein and are linked to autism spectrum disorder, intellectual disability and speech impairment (gong2024mark2variantscause pages 8-9)

References

1. (deng2015proteinkinasea pages 8-10): Si-si Deng, Le Wu, Ya-Chao Wang, Peng Cao, Lei Xu, Qian-Ru Li, Mengqi Liu, Lun Zhang, Yuejing Jiang, Xiao-yu Yang, Sheng-Nan Sun, M. Tan, M. Qian, Yi Zang, Linyin Feng, and Jia Li. Protein kinase a rescues microtubule affinity-regulating kinase 2-induced microtubule instability and neurite disruption by phosphorylating serine 409*. The Journal of Biological Chemistry, 290:3149-3160, Dec 2015. URL: https://doi.org/10.1074/jbc.m114.629873, doi:10.1074/jbc.m114.629873. This article has 14 citations.

2. (gong2024mark2variantscause pages 8-9): M. Gong, Jiayi Li, Zailong Qin, Matheus Vernet Machado Bressan Wilke, Yijun Liu, Qian Li, Haoran Liu, Chen Liang, Joel A Morales-Rosado, A. S. Cohen, Susan S. Hughes, B. R. Sullivan, Valerie Waddell, M. H. van den Boogaard, R. V. van Jaarsveld, E. van Binsbergen, K. V. van Gassen, Tianyun Wang, S. Hiatt, M. D. Amaral, W. Kelley, Jianbo Zhao, Weixing Feng, C. Ren, Yazhen Yu, N. Boczek, M. J. Ferber, C. Lahner, S. Elliott, Y. Ruan, C. Mignot, B. Keren, Hua Xie, Xiaoyan Wang, B. Popp, Christiane Zweier, J. Piard, C. Coubes, F. T. Mau-Them, H. Safraou, A. M. Innes, J. Gauthier, Jacques L Michaud, Daniel C. Koboldt, Odent Sylvie, Marjolaine Willems, Wen-Hann Tan, B. Cogné, Claudine Rieubland, Dominique Braun, Scott McLean, K. Platzer, P. Zacher, Henry Oppermann, Lucie Evenepoel, Pierre Blanc, Laïla El Khattabi, Neshatul Haque, Nikita R. Dsouza, Michael T. Zimmermann, Raul Urrutia, Eric W. Klee, Yiping Shen, Hongzhen Du, Leonard Rappaport, Chang-Mei Liu, and Xiaoli Chen. Mark2 variants cause autism spectrum disorder via the downregulation of wnt/β-catenin signaling pathway. American Journal of Human Genetics, 111:2392-2410, Oct 2024. URL: https://doi.org/10.1016/j.ajhg.2024.09.006, doi:10.1016/j.ajhg.2024.09.006. This article has 5 citations and is from a highest quality peer-reviewed journal.

3. (jenardhanan2014thestructuralanalysis pages 13-15): Pranitha Jenardhanan, Jayakanthan Mannu, and Premendu P. Mathur. The structural analysis of mark4 and the exploration of specific inhibitors for the mark family: a computational approach to obstruct the role of mark4 in prostate cancer progression. Molecular bioSystems, 10 7:1845-68, Jun 2014. URL: https://doi.org/10.1039/c3mb70591a, doi:10.1039/c3mb70591a. This article has 43 citations and is from a peer-reviewed journal.

4. (marx2006structuralvariationsin pages 1-1): A. Marx, C. Nugoor, Jens Müller, S. Panneerselvam, T. Timm, Matthias Bilang, E. Mylonas, D. Svergun, E. Mandelkow, and E. Mandelkow. Structural variations in the catalytic and ubiquitin-associated domains of microtubule-associated protein/microtubule affinity regulating kinase (mark) 1 and mark2*. Journal of Biological Chemistry, 281:27586-27599, Sep 2006. URL: https://doi.org/10.1074/jbc.m604865200, doi:10.1074/jbc.m604865200. This article has 71 citations and is from a domain leading peer-reviewed journal.

5. (panneerselvam2006structureofthe pages 1-2): S. Panneerselvam, A. Marx, E. Mandelkow, and E. Mandelkow. Structure of the catalytic and ubiquitin-associated domains of the protein kinase mark/par-1. Structure, 14 2:173-83, Feb 2006. URL: https://doi.org/10.1016/j.str.2005.09.022, doi:10.1016/j.str.2005.09.022. This article has 93 citations and is from a domain leading peer-reviewed journal.

6. (gong2024mark2variantscause pages 3-4): M. Gong, Jiayi Li, Zailong Qin, Matheus Vernet Machado Bressan Wilke, Yijun Liu, Qian Li, Haoran Liu, Chen Liang, Joel A Morales-Rosado, A. S. Cohen, Susan S. Hughes, B. R. Sullivan, Valerie Waddell, M. H. van den Boogaard, R. V. van Jaarsveld, E. van Binsbergen, K. V. van Gassen, Tianyun Wang, S. Hiatt, M. D. Amaral, W. Kelley, Jianbo Zhao, Weixing Feng, C. Ren, Yazhen Yu, N. Boczek, M. J. Ferber, C. Lahner, S. Elliott, Y. Ruan, C. Mignot, B. Keren, Hua Xie, Xiaoyan Wang, B. Popp, Christiane Zweier, J. Piard, C. Coubes, F. T. Mau-Them, H. Safraou, A. M. Innes, J. Gauthier, Jacques L Michaud, Daniel C. Koboldt, Odent Sylvie, Marjolaine Willems, Wen-Hann Tan, B. Cogné, Claudine Rieubland, Dominique Braun, Scott McLean, K. Platzer, P. Zacher, Henry Oppermann, Lucie Evenepoel, Pierre Blanc, Laïla El Khattabi, Neshatul Haque, Nikita R. Dsouza, Michael T. Zimmermann, Raul Urrutia, Eric W. Klee, Yiping Shen, Hongzhen Du, Leonard Rappaport, Chang-Mei Liu, and Xiaoli Chen. Mark2 variants cause autism spectrum disorder via the downregulation of wnt/β-catenin signaling pathway. American Journal of Human Genetics, 111:2392-2410, Oct 2024. URL: https://doi.org/10.1016/j.ajhg.2024.09.006, doi:10.1016/j.ajhg.2024.09.006. This article has 5 citations and is from a highest quality peer-reviewed journal.

7. (jenardhanan2014thestructuralanalysis pages 23-25): Pranitha Jenardhanan, Jayakanthan Mannu, and Premendu P. Mathur. The structural analysis of mark4 and the exploration of specific inhibitors for the mark family: a computational approach to obstruct the role of mark4 in prostate cancer progression. Molecular bioSystems, 10 7:1845-68, Jun 2014. URL: https://doi.org/10.1039/c3mb70591a, doi:10.1039/c3mb70591a. This article has 43 citations and is from a peer-reviewed journal.

8. (matenia2009thetauof pages 1-2): Dorthe Matenia and Eva-Maria Mandelkow. The tau of mark: a polarized view of the cytoskeleton. Trends in Biochemical Sciences, 34:332-342, Jul 2009. URL: https://doi.org/10.1016/j.tibs.2009.03.008, doi:10.1016/j.tibs.2009.03.008. This article has 252 citations and is from a domain leading peer-reviewed journal.

9. (panneerselvam2006structureofthe pages 8-9): S. Panneerselvam, A. Marx, E. Mandelkow, and E. Mandelkow. Structure of the catalytic and ubiquitin-associated domains of the protein kinase mark/par-1. Structure, 14 2:173-83, Feb 2006. URL: https://doi.org/10.1016/j.str.2005.09.022, doi:10.1016/j.str.2005.09.022. This article has 93 citations and is from a domain leading peer-reviewed journal.

10. (sugiyama2019largescalediscoveryof pages 6-8): Naoyuki Sugiyama, Haruna Imamura, and Yasushi Ishihama. Large-scale discovery of substrates of the human kinome. Scientific Reports, Jul 2019. URL: https://doi.org/10.1038/s41598-019-46385-4, doi:10.1038/s41598-019-46385-4. This article has 120 citations and is from a poor quality or predatory journal.

11. (timm2008structureandregulation pages 4-5): Thomas Timm, Alexander Marx, Saravanan Panneerselvam, Eckhard Mandelkow, and Eva-Maria Mandelkow. Structure and regulation of mark, a kinase involved in abnormal phosphorylation of tau protein. BMC Neuroscience, Dec 2008. URL: https://doi.org/10.1186/1471-2202-9-s2-s9, doi:10.1186/1471-2202-9-s2-s9. This article has 84 citations and is from a peer-reviewed journal.

12. (unknownauthors2007regulationofthe pages 7-11): Regulation of the kinase MARK from Rattus norvegicus (Brekenhout, 1769) by GSK3

13. (wijk2020thefirsteukaryotic pages 5-8): Leny M. van Wijk and Berend Snel. The first eukaryotic kinome tree illuminates the dynamic history of present-day kinases. BioRxiv, Jan 2020. URL: https://doi.org/10.1101/2020.01.27.920793, doi:10.1101/2020.01.27.920793. This article has 12 citations.

14. (ahrari2017interconversionofinactive pages 19-21): S. Ahrari, Navid Mogharrab, and Leila Navapour. Interconversion of inactive to active conformation of mark2: insights from molecular modeling and molecular dynamics simulation. Archives of biochemistry and biophysics, 630:66-80, Sep 2017. URL: https://doi.org/10.1016/j.abb.2017.07.002, doi:10.1016/j.abb.2017.07.002. This article has 12 citations and is from a peer-reviewed journal.

15. (annadurai2017microtubuleaffinityregulatingkinases pages 11-11): Narendran Annadurai, Khushboo Agrawal, Petr Džubák, Marián Hajdúch, and Viswanath Das. Microtubule affinity-regulating kinases are potential druggable targets for alzheimer’s disease. Cellular and Molecular Life Sciences, 74:4159-4169, Jun 2017. URL: https://doi.org/10.1007/s00018-017-2574-1, doi:10.1007/s00018-017-2574-1. This article has 48 citations and is from a domain leading peer-reviewed journal.

16. (jenardhanan2014thestructuralanalysis pages 21-23): Pranitha Jenardhanan, Jayakanthan Mannu, and Premendu P. Mathur. The structural analysis of mark4 and the exploration of specific inhibitors for the mark family: a computational approach to obstruct the role of mark4 in prostate cancer progression. Molecular bioSystems, 10 7:1845-68, Jun 2014. URL: https://doi.org/10.1039/c3mb70591a, doi:10.1039/c3mb70591a. This article has 43 citations and is from a peer-reviewed journal.

17. (panneerselvam2006structureofthe pages 11-11): S. Panneerselvam, A. Marx, E. Mandelkow, and E. Mandelkow. Structure of the catalytic and ubiquitin-associated domains of the protein kinase mark/par-1. Structure, 14 2:173-83, Feb 2006. URL: https://doi.org/10.1016/j.str.2005.09.022, doi:10.1016/j.str.2005.09.022. This article has 93 citations and is from a domain leading peer-reviewed journal.

18. (unknownauthors2006structuralvariationsin pages 10-13): Structural variations in the catalytic and ubiquitin associated domains of MARK1 and MARK2
